Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF, STEP 1 Study Group. · 2022
Read Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. by Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF, STEP 1 Study Group. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9542252.txt.
Description
Wilding and co-authors track weight regain after semaglutide withdrawal in the STEP 1 trial extension. The main trial randomized 1961 adults with obesity to weekly semaglutide or placebo. Treatment ran 68 weeks next to lifestyle support. The extension then stopped all treatment and watched for a year.
The extension covered 327 participants from the main trial. By week 68, mean weight loss was 17.3% on semaglutide and 2.0% on placebo. After withdrawal, the semaglutide group regained 11.6 percentage points by week 120. Net loss from the start was then just 5.6%. Heart and metabolic gains also slid back toward baseline. The authors read this as proof that obesity is chronic. Lasting gains need ongoing treatment, they conclude. The subset came from sites in five countries with top recruitment.
Catalog record
| CREATOR | Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF, STEP 1 Study Group. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |